

28 October 2013

The Company Announcements Office
ASX Limited

Notice under section 708A(5)(e) of the Corporations Act

On 28 October 2013, Neuren Pharmaceuticals Limited (the Company) issued 187 million fully paid ordinary shares to various institutional and sophisticated investors at an issue price of 11.5 cents per share (Placement). Details of the Placement are set out in the Appendix 3B lodged on 28 October 2013 and the Company's ASX announcement lodged on 22 October 2013.

The Company gives this Notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act).

1. The shares the subject of the Placement, were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
2. As at the date of this Notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. section 674 of the Corporations Act.
3. As at the date of this Notice, there is no excluded information for the purposes of section 708A(7) and section 708A(8) of the Corporations Act.

Yours sincerely

A handwritten signature in black ink, appearing to read "Jon Pilcher", enclosed in a thin black rectangular border.

Jon Pilcher
CFO & Company Secretary
Neuren Pharmaceuticals